An Absolute Bioavailability Study of Baricitinib in Healthy Subjects Using the Intravenous Tracer Method
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Baricitinib (Primary) ; Baricitinib (Primary)
- Indications Diabetic nephropathies; Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 19 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 20 Jan 2015 New trial record